Related Experiment Video
Updated: Jul 3, 2026
12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
Screening of Cationic Short Peptide RKIIIRW and Its Antimelanoma Nano Delivery System
Dayang Wang1, Pengbao Shi1, Jiashuo Ye1
1College of Chemistry and Chemical Engineering, College of Materials Science and Engineering, Institute of Biomedical Materials and Engineering, Qingdao University, Qingdao266071, China.
Biomacromolecules
|July 1, 2026
Summary
Researchers developed a novel nanodrug delivery system using mesoporous silica nanoparticles (MSNs) for melanoma treatment. This system enhances cationic peptide efficacy against melanoma cells while minimizing side effects.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Melanoma is a highly lethal cancer with limited treatment options.
- Cationic peptides show promise for melanoma treatment but require effective delivery systems.
- Mesoporous silica nanoparticles (MSNs) offer high drug loading capacity and tunable properties.
Purpose of the Study:
- To develop a targeted and controllable nanodrug delivery system for melanoma.
- To enhance the therapeutic efficacy of the cationic peptide RKIIIRW.
- To minimize systemic side effects associated with melanoma treatment.
Main Methods:
- Screening of cationic short peptide RKIIIRW using solid-phase synthesis, MTT assay, and cell membrane chromatography.
- Fabrication of MSNs with polydopamine (PDA) coating for stability and controlled release.
- Functionalization of MSNs with hyaluronic acid (HA) for targeted delivery to tumor cells.
Main Results:
- Successful synthesis and characterization of RKIIIRW peptide with potent B16F10 cell inhibition.
- Development of PDA-coated and HA-functionalized MSNs for enhanced drug loading and targeted delivery.
- Demonstration of improved therapeutic efficacy and reduced side effects of the nanodrug delivery system in preclinical models.
Conclusions:
- The developed nanodrug delivery system effectively targets melanoma cells and enhances the therapeutic potential of cationic peptides.
- Surface modification with PDA and HA improves drug stability, targeting, and cellular uptake.
- This novel system represents a promising strategy for improved melanoma treatment with minimized adverse effects.
